Brief: Nanobiotix Reports Updated Phase 1 Anti-PD-1 Combination Data

Nanobiotix SA

10/11/2022 08:24

Nov 10 (Reuters) - NANOBIOTIX SA  NANOB.PA :
    * NANOBIOTIX REPORTS UPDATED PHASE 1 ANTI-PD-1 COMBINATION
DATA
THAT MAY SUPPORT THE IMMUNE STIMULATION POTENTIAL OF
RADIOENHANCER NBTXR3 AT THE 37TH ANNUAL MEETING OF THE SOCIETY
FOR IMMUNOTHERAPY OF CANCER
    * OBJECTIVE REDUCTION FROM BASELINE IN ALL TARGET LESIONS
("OBJECTIVE REDUCTION") WAS OBSERVED IN 71.43% OF EVALUABLE
PATIENTS (15/21) AND OBJECTIVE REDUCTION OF MORE THAN 30% WAS
OBSERVED IN 42.86% OF EVALUABLE PATIENTS (9/21)
    * OBJECTIVE REDUCTION WAS OBSERVED IN 66.66% OF EVALUABLE
PATIENTS
WITH CANCER RESISTANT TO ANTI-PD-1 (10/15)
    * AS OF CUTOFF, SYSTEMIC DISEASE CONTROL WAS DURABLE AND HAD
SUSTAINED FOR MORE THAN 6 MONTHS IN 38.10% OF EVALUABLE PATIENTS
(8/21)
    * RESULTS INCLUDE 5 ADDITIONAL PATIENTS OF 21 EVALUABLE AS
OF DATA
CUTOFF ON 22 AUGUST 2022 AND CONTINUE TO SUGGEST LOCAL CONTROL
AND IMMUNE STIMULATION REGARDLESS OF PRIOR ANTI-PD-1 EXPOSURE
    * DATA SHOW THAT RADIOTHERAPY-ACTIVATED NBTXR3 FOLLOWED BY
ANTI-PD-1 WAS FEASIBLE AND WELL TOLERATED IN COMPLETE DOSE
ESCALATION PART OF COMPANY'S PHASE 1 IMMUNOTHERAPY STUDY WITH A
RECOMMENDED PHASE 2 DOSE ESTABLISHED AT 33% OF GROSS TUMOR
VOLUME IN ALL 3 COHORTS

Source text for Eikon:  ID:nGNX3mnMVC 
Further company coverage:  NANOB.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))